Viewing Study NCT00880893


Ignite Creation Date: 2025-12-25 @ 1:11 AM
Ignite Modification Date: 2025-12-27 @ 1:51 AM
Study NCT ID: NCT00880893
Status: COMPLETED
Last Update Posted: 2022-03-21
First Post: 2009-04-13
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore
Sponsor: Sanofi Pasteur, a Sanofi Company
Organization:

Study Overview

Official Title: Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore
Status: COMPLETED
Status Verified Date: 2022-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Primary Objectives:

* To evaluate safety after each CYD Dengue vaccination in terms of injection site and systemic reactogenicity.
* To evaluate the occurrence of Serious Adverse Events (SAEs) throughout the trial period.
* To evaluate the humoral immune response to each CYD Dengue serotype after each vaccination in a subset of participants.

Secondary Objectives:

* To evaluate the persistence of the humoral immune response during 4 years after the last vaccination in a subset of participants.
Detailed Description: This was a multicenter trial involving three vaccinations one each at 0, 6 and 12 months over a period of 1 year, and a 4-year follow-up following the last vaccination.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2014-001713-26 EUDRACT_NUMBER None View